X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2479432D
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company's lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also develops X4P-001, a CXCR4 inhibitor used for the treatment of melanoma, refractory clear cell renal cell carcinoma (ccRCC), and other solid tumor indications. X4 Pharma's pre-clinical products include X4P-002, designed for the treatment of brain cancers including glioblastoma multiforme. X4 Pharma is headquartered in Cambridge, Massachusetts, the US.

X4 Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

X4 Pharma Raises USD25.8 Million in Venture Financing 11

X4 Pharma Raises USD37.5 Million in Series A Financing Round 12

X4 Pharma Raises USD0.7 Million in Seed Financing Round 13

Partnerships 14

X4 Pharma Enters into Research Agreement with Yale University 14

Licensing Agreements 15

X4 Pharma Enters into Licensing Agreement with Sanofi 15

Equity Offering 16

X4 Pharma Spin Off from Sanofi 16

X4 Pharmaceuticals Inc-Key Competitors 17

X4 Pharmaceuticals Inc-Key Employees 18

X4 Pharmaceuticals Inc-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Corporate Communications 20

Nov 05, 2018: X4 Pharmaceuticals appoints Gary J. Bridger, PhD, to board of directors 20

Jul 12, 2018: X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors 21

Jan 23, 2017: X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer 22

Product News 23

11/16/2017: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting 23

10/30/2017: Clinical Data for X4P-001-IO in Combination with Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma 24

08/31/2017: First Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the European Society of Medical Oncology 2017 Congress 25

05/25/2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 26

05/17/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM Syndrome 27

05/16/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma 28

05/08/2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab) 29

04/16/2018: X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity 30

01/30/2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 31

01/26/2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 32

Clinical Trials 33

Mar 15, 2018: X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting 33

Dec 11, 2017: First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary Immunodeficiency Disease 34

Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 35

Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 36

Oct 25, 2017: Updated Clinical Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 37

Sep 11, 2017: Initial Clinical Trial Data for Combination of X4P-001-IO and Inlyta (Axitinib) Demonstrate Encouraging Disease Control Rates and Durable Clinical Responses in Patients with Clear Cell Renal Cell Carcinoma 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39

List of Figures

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

X4 Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

X4 Pharma Raises USD25.8 Million in Venture Financing 11

X4 Pharma Raises USD37.5 Million in Series A Financing Round 12

X4 Pharma Raises USD0.7 Million in Seed Financing Round 13

X4 Pharma Enters into Research Agreement with Yale University 14

X4 Pharma Enters into Licensing Agreement with Sanofi 15

X4 Pharma Spin Off from Sanofi 16

X4 Pharmaceuticals Inc, Key Competitors 17

X4 Pharmaceuticals Inc, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

X4 Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com